Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review
Open Access
- 19 May 2023
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 41 (8) , 913-943
Abstract
Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia. Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via rate or rhythm control. This study aimed to review the literature on the cost effectiveness of treatment strategies to manage AF among adults living in low-, middle- and high-income countries. Methods We searched MEDLINE (OvidSp), Embase, Web of Science, Cochrane Library, EconLit and Google Scholar for relevant studies between September 2022 and November 2022. The search strategy involved medical subject headings or related text words. Data management and selection was performed using EndNote library. The titles and abstracts were screened followed by eligibility assessment of full texts. Selection, assessment of the risk of bias within the studies, and data extraction were conducted by two independent reviewers. The cost-effectiveness results were synthesised narratively. The analysis was performed using Microsoft Excel 365. The incremental cost effectiveness ratio for each study was adjusted to 2021 USD values. Results Fifty studies were included in the analysis after selection and risk of bias assessment. In high-income countries, apixaban was predominantly cost effective for stroke prevention in patients at low and moderate risk of stroke, while left atrial appendage closure (LAAC) was cost effective in patients at high risk of stroke. Propranolol was the cost-effective choice for rate control, while catheter ablation and the convergent procedure were cost-effective strategies in patients with paroxysmal and persistent AF, respectively. Among the anti-arrhythmic drugs, sotalol was the cost-effective strategy for rhythm control. In middle-income countries, apixaban was the cost-effective choice for stroke prevention in patients at low and moderate risk of stroke while high-dose edoxaban was cost effective in patients at high risk of stroke. Radiofrequency catheter ablation was the cost-effective option in rhythm control. No data were available for low-income countries. Conclusion This systematic review has shown that there are several cost-effective strategies to manage AF in different resource settings. However, the decision to use any strategy should be guided by objective clinical and economic evidence supported by sound clinical judgement. Registration CRD42022360590.Keywords
Funding Information
- Griffith University (Health Group Seed Grant)
- National Health and Medical Research Council (GNT1135894, GNT1136923)
- Griffith University
This publication has 76 references indexed in Scilit:
- Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2013
- Stroke Prevention in Non-Valvular Atrial Fibrillation: Systematic Review of Cost-Effectiveness StudiesValue in Health, 2013
- The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluationsBMC Cardiovascular Disorders, 2013
- Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st centuryInternational Journal of Cardiology, 2013
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial FibrillationStroke, 2013
- Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial FibrillationValue in Health, 2013
- Cost-effectiveness of newer anticoagulants for stroke prevention in atrial fibrillation: A systematic literature reviewValue in Health, 2013
- Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Systematic Review of Cost-Effectiveness ModelsPLOS ONE, 2013
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation ? results from the RAte Control versus Electrical cardioversion (RACE) studyEuropean Heart Journal, 2004